1-20 of 35
Jedd D. Wolchok
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study

James W. Smithy, Hannah L. Kalvin, Fiona D. Ehrich, Ronak Shah, Matthew Adamow, Vladislav Raber, Collen A. Maher, Jenna Kleman, Deborah A.G. McIntyre, Alexander N. Shoushtari, Allison Betof Warner, Margaret K. Callahan, Parisa Momtaz, Omar Eton, Suresh Nair, Jedd D. Wolchok, Paul B. Chapman, Michael F. Berger, Katherine S. Panageas, Michael A. Postow
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (16): 3407–3415.
https://doi.org/10.1158/1078-0432.CCR-23-3643
Published: 15 August 2024
View article titled, Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study
Open the PDF for Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study in another window
Includes: Supplementary data
Journal Articles

Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

David S. Hong, Michael Postow, Bartosz Chmielowski, Ryan Sullivan, Amita Patnaik, Ezra E.W. Cohen, Geoffrey Shapiro, Conor Steuer, Martin Gutierrez, Heather Yeckes-Rodin, Robert Ilaria, Jr, Brenda O'Connell, Joanna Peng, Guangbin Peng, Nora Zizlsperger, Anthony Tolcher, Jedd D. Wolchok
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (12): 2210–2219.
https://doi.org/10.1158/1078-0432.CCR-22-3313
Published: 13 June 2023
View article titled, Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial
Open the PDF for Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial in another window
Includes: Supplementary data
Journal Articles

Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma

Alexander N. Shoushtari, Anthony J. Olszanski, Marta Nyakas, Thomas J. Hornyak, Jedd D. Wolchok, Victor Levitsky, Lukasz Kuryk, Thomas B. Hansen, Magnus Jäderberg
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 100–109.
https://doi.org/10.1158/1078-0432.CCR-22-2046
Published: 04 January 2023
View article titled, Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
Open the PDF for Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors

Diwakar Davar, Roberta Zappasodi, Hong Wang, Girish S. Naik, Takami Sato, Todd Bauer, David Bajor, Olivier Rixe, Walter Newman, Jingjing Qi, Aliya Holland, Phillip Wong, Lianna Sifferlen, Diane Piper, Cynthia A. Sirard, Taha Merghoub, Jedd D. Wolchok, Jason J. Luke
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 3990–4002.
https://doi.org/10.1158/1078-0432.CCR-22-0339
Published: 15 September 2022
View article titled, Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Open the PDF for Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

Alexander N. Shoushtari, Walid K. Chatila, Arshi Arora, Francisco Sanchez-Vega, Havish S. Kantheti, Jorge A. Rojas Zamalloa, Penina Krieger, Margaret K. Callahan, Allison Betof Warner, Michael A. Postow, Parisa Momtaz, Suresh Nair, Charlotte E. Ariyan, Christopher A. Barker, Mary Susan Brady, Daniel G. Coit, Neal Rosen, Paul B. Chapman, Klaus J. Busam, David B. Solit, Katherine S. Panageas, Jedd D. Wolchok, Nikolaus Schultz
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2226–2235.
https://doi.org/10.1158/1078-0432.CCR-20-4189
Published: 15 April 2021
View article titled, Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas
Open the PDF for Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas in another window
Includes: Supplementary data
Journal Articles

Abstract IA04: COVID-19 in patients with lung cancers in New York City

Jia Luo, Hira Rizvi, Isabel R. Preeshagul, Jacklynn V. Egger, David Hoyos, Chaitanya Bandlamudi, Mark T.A. Donoghue, Marta Łuksza, Benjamin D. Greenbaum, Jedd D. Wolchok, Mark G. Kris, Matthew D. Hellmann
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): IA04.
https://doi.org/10.1158/1557-3265.COVID-19-IA04
Published: 15 September 2020
View article titled, Abstract IA04: COVID-19 in patients with lung cancers in New York City
Journal Articles

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Michele Maio, Omid Hamid, James Larkin, Alessia Covre, Maresa Altomonte, Luana Calabrò, Santosh A. Vardhana, Caroline Robert, Ramy Ibrahim, Andrea Anichini, Jedd D. Wolchok, Anna Maria Di Giacomo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (16): 4201–4205.
https://doi.org/10.1158/1078-0432.CCR-20-1657
Published: 14 August 2020
View article titled, Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era
Open the PDF for Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era in another window
Journal Articles

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma

Michael A. Postow, Susan J. Knox, Debra A. Goldman, Yuval Elhanati, Vikram Mavinkurve, Phillip Wong, Darragh Halpenny, Sunil K. Reddy, Kenya Vado, Danielle McCabe, Kristen Aufiero Ramirez, Mary Macri, Paul Schwarzenberger, Toni Ricciardi, Aileen Ryan, Ralph Venhaus, Parisa Momtaz, Alexander N. Shoushtari, Margaret K. Callahan, Paul B. Chapman, Jedd D. Wolchok, Priyanka B. Subrahmanyam, Holden T. Maecker, Katherine S. Panageas, Christopher A. Barker
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3193–3201.
https://doi.org/10.1158/1078-0432.CCR-19-3936
Published: 01 July 2020
View article titled, A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Open the PDF for A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma in another window
Includes: Supplementary data
Journal Articles

Immunotherapy of Melanoma: Facts and Hopes

Sarah A. Weiss, Jedd D. Wolchok, Mario Sznol
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5191–5201.
https://doi.org/10.1158/1078-0432.CCR-18-1550
Published: 03 September 2019
View article titled, Immunotherapy of Melanoma: Facts and Hopes
Open the PDF for Immunotherapy of Melanoma: Facts and Hopes in another window
Journal Articles

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 6098.
https://doi.org/10.1158/1078-0432.CCR-18-3340
Published: 03 December 2018
View article titled, Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Journal Articles

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Richard W. Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, S. Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (20): 4960–4967.
https://doi.org/10.1158/1078-0432.CCR-17-2386
Published: 15 October 2018
View article titled, Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Open the PDF for Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab in another window
Includes: Supplementary data
Journal Articles

Introducing a New Series: Immunotherapy Facts and Hopes

Ignacio Melero, Mario Sznol, Marlowe S. Tessmer, Theresa L. Whiteside, Jedd D. Wolchok
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1773–1774.
https://doi.org/10.1158/1078-0432.CCR-18-0408
Published: 12 April 2018
View article titled, Introducing a New Series: Immunotherapy Facts and Hopes
Open the PDF for Introducing a New Series: Immunotherapy Facts and Hopes in another window
Journal Articles

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling

Heather L. McArthur, Adi Diab, David B. Page, Jianda Yuan, Stephen B. Solomon, Virgilio Sacchini, Christopher Comstock, Jeremy C. Durack, Majid Maybody, Janice Sung, Arielle Ginsberg, Phillip Wong, Afsar Barlas, Zhiwan Dong, Chunjun Zhao, Brian Blum, Sujata Patil, Deirdre Neville, Elizabeth A. Comen, Elizabeth A. Morris, Alan Kotin, Edi Brogi, Y. Hannah Wen, Monica Morrow, Mario E. Lacouture, Padmanee Sharma, James P. Allison, Clifford A. Hudis, Jedd D. Wolchok, Larry Norton
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (23): 5729–5737.
https://doi.org/10.1158/1078-0432.CCR-16-0190
Published: 30 November 2016
View article titled, A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
Open the PDF for A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling in another window
Journal Articles

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Benjamin Weide, Alexander Martens, Jessica C. Hassel, Carola Berking, Michael A. Postow, Kees Bisschop, Ester Simeone, Johanna Mangana, Bastian Schilling, Anna Maria Di Giacomo, Nicole Brenner, Katharina Kähler, Lucie Heinzerling, Ralf Gutzmer, Armin Bender, Christoffer Gebhardt, Emanuela Romano, Friedegund Meier, Peter Martus, Michele Maio, Christian Blank, Dirk Schadendorf, Reinhard Dummer, Paolo A. Ascierto, Geke Hospers, Claus Garbe, Jedd D. Wolchok
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (22): 5487–5496.
https://doi.org/10.1158/1078-0432.CCR-16-0127
Published: 14 November 2016
View article titled, Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Open the PDF for Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab in another window
Includes: Supplementary data
Journal Articles

An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

Danny N. Khalil, Michael A. Postow, Nageatte Ibrahim, Dale L. Ludwig, Jan Cosaert, Siva Rama Prasad Kambhampati, Shande Tang, Dmitri Grebennik, John Sae Wook Kauh, Heinz-Josef Lenz, Keith T. Flaherty, F. Stephen Hodi, Donald P. Lawrence, Jedd D. Wolchok
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (21): 5204–5210.
https://doi.org/10.1158/1078-0432.CCR-16-1241
Published: 31 October 2016
View article titled, An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
Open the PDF for An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma in another window
Includes: Supplementary data
Journal Articles

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

Alexander Martens, Kilian Wistuba-Hamprecht, Jianda Yuan, Michael A. Postow, Phillip Wong, Mariaelena Capone, Gabriele Madonna, Amir Khammari, Bastian Schilling, Antje Sucker, Dirk Schadendorf, Peter Martus, Brigitte Dreno, Paolo A. Ascierto, Jedd D. Wolchok, Graham Pawelec, Claus Garbe, Benjamin Weide
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (19): 4848–4858.
https://doi.org/10.1158/1078-0432.CCR-16-0249
Published: 02 October 2016
View article titled, Increases in Absolute Lymphocytes and Circulating CD4<sup>+</sup> and CD8<sup>+</sup> T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
Open the PDF for Increases in Absolute Lymphocytes and Circulating CD4<sup>+</sup> and CD8<sup>+</sup> T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab in another window
Includes: Supplementary data
Journal Articles

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

Alexander Martens, Kilian Wistuba-Hamprecht, Marnix Geukes Foppen, Jianda Yuan, Michael A. Postow, Phillip Wong, Emanuela Romano, Amir Khammari, Brigitte Dreno, Mariaelena Capone, Paolo A. Ascierto, Anna Maria Di Giacomo, Michele Maio, Bastian Schilling, Antje Sucker, Dirk Schadendorf, Jessica C. Hassel, Thomas K. Eigentler, Peter Martus, Jedd D. Wolchok, Christian Blank, Graham Pawelec, Claus Garbe, Benjamin Weide
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2908–2918.
https://doi.org/10.1158/1078-0432.CCR-15-2412
Published: 14 June 2016
View article titled, Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Open the PDF for Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab in another window
Includes: Supplementary data
Journal Articles

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors

Melinda S. Merchant, Matthew Wright, Kristin Baird, Leonard H. Wexler, Carlos Rodriguez-Galindo, Donna Bernstein, Cindy Delbrook, Maya Lodish, Rachel Bishop, Jedd D. Wolchok, Howard Streicher, Crystal L. Mackall
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1364–1370.
https://doi.org/10.1158/1078-0432.CCR-15-0491
Published: 14 March 2016
View article titled, Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Open the PDF for Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

CCR 20th Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology

Axel Hoos, Jedd D. Wolchok, Rachel W. Humphrey, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (22): 4989–4991.
https://doi.org/10.1158/1078-0432.CCR-14-3128
Published: 12 November 2015
View article titled, <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology
Open the PDF for <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology in another window
Journal Articles

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, Rene Gonzalez, Jose Lutzky, Steven J. O'Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil Ramaiya, Anita Giobbie-Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, F. Stephen Hodi
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2289–2296.
https://doi.org/10.1158/1078-0432.CCR-14-1630
Published: 14 May 2015
View article titled, Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition
Open the PDF for Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition in another window
Includes: Supplementary data